Fresenius Share Reaction to FDA Warning Letter Seems Overdone — Market Talk

Fresenius investors might have overreacted to news that the FDA sent a warning letter to the German healthcare group's Kabi pharmaceutical business alerting it to what the regulator called serious violations at a U.S. facility, Citi analysts say in a research note. Fresenius Kabi said in response t…